.tb-field[data-toolset-blocks-field="203299a22ab9b4467746e3ecd5032d31"] { font-size: 14px; }  h3.tb-heading[data-toolset-blocks-heading="c64a8eae195c288bfd5aec4150db92c6"]  { font-size: 16px; }  .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="cdfd4c4737b2898eba4443dd59a1bf50"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="ed3832aa6201cbec5b1e5b902dc067e2"] { padding: 25px; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { background-color: rgba( 243, 241, 241, 1 );border-radius: 3px;padding: 10px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 221, 219, 219, 1 );display: flex; } .tb-field[data-toolset-blocks-field="b4905723ecea41184171014c65948a9a"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="c949bea6c10cb48f79d87a6418026524"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="f8b4df145ada4a882c0769270c620213"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} @media only screen and (max-width: 781px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } @media only screen and (max-width: 599px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } 

Sphere Fluidics

Sphere Fluidics is an established Life Sciences company providing single cell analysis and monoclonality assurance systems for biotherapeutic discovery and development.

Sphere Fluidics Cyto-Mine^®, is a fully integrated device which can accelerate biologics discovery and cell line development by streamlining cell isolation, assay, sorting, imaging and dispensing into one automated process which reduces timelines, increases screening capabilities and assures monoclonality.

Cyto-Mine^®, underpinned by the Companys patented picodroplet technology, integrates selective screening of tens of millions of single cells in miniaturised aqueous pL compartments called picodroplets. Within the picodroplets, single cells are assayed to identify valuable proteins (e.g. antibodies) to find rare cells of interest or cells with high productivity. Cyto-Mine^® can selectively sort the hits and during subsequent dispensing into individual microtitre plate wells, image the picodroplets for assurance of monoclonality.

Cyto-Mine^® provides a solution to resource-intensive, time-consuming and expensive workflows by streamlining cell isolation, titre determination and clonality assurance while reducing costs for biopharmaceutical discovery and development. Using picodroplet microfluidic technology, Sphere Fluidics is developing a novel system that will automate and miniaturise many of the steps in the single cell engineering using synthetic biology or genome editing, to enhance the generation of high-quality precision engineered cells in a high-throughput manner.

Sphere Fluidics has 30 employees based in labs and offices in Babraham (Cambridgeshire, UK) and Monmouth Junction (New Jersey, USA) and has signed international distributorships in all other major markets.

Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program

Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D 27 January 2025 – Cambridge, UK – Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the...

Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America

Significant expansion of global commercial leadership team led by new CEO, Dale Levitzke, to address global demand for the Cyto-Mine Chroma platform 14 November 2024 – Cambridge, UK – Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global...

Sphere Fluidics awarded Gold accreditation by Investors in People

Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally 14 June, 2024 - Cambridge, UK - Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced that it has received the ‘We invest in people’ Gold accreditation, a prestigious...

Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

4 June 2024 - Cambridge, UK - Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-CellectPLUS. In conjunction with the Company’s Cyto-Mine platform, the new assay provides a streamlined method to measure antibody production in single cells by rapidly detecting secreted human IgG, enabling...

Sphere Fluidics appoints Curtis Nicholson as director of Sales, EMEA, to support accelerated growth in key markets

23 May 2024 -- Cambridge, UK -- Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Curtis Nicholson as director of Sales for Europe, Middle East and Africa (EMEA). Curtis’ appointment will strengthen the company’s market position in these regions as it progresses ambitious plans...

Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer

Dale Levitzke joins as Dr Frank F Craig, current CEO and co-founder, announces his retirement after leading the company for 14 years 30 April 2024 -- Cambridge, UK -- Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Dale Levitzke as CEO with immediate effect,...

Sphere Fluidics appoints Edward Rayner as non-executive director

Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth 17 April 2024 – Cambridge, UK – Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a...

Sphere Fluidics appoints Dr Graeme Daniels as Vice President of Sales and Marketing

Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions 13 December 2023 – Cambridge, UK – Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, is pleased to announce the appointment of Dr Graeme Daniels, PhD, as the new vice president of...

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions 3 October 2023 – Cambridge, UK, and Porto, Portugal – Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine platform has been selected by FairJourney...

Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy

Cambridge, UK, 23rd May 2023: Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy. The update has been introduced to better reflect the Companyís customer-centric approach and showcase its pioneering single cell discovery...